Direct Evidence that Myocardial Insulin Resistance following Myocardial Ischemia Contributes to Post-Ischemic Heart Failure

Feng Fu1,2,*, Kun Zhao3,*, Jia Li1, Jie Xu1, Yuan Zhang1, Chengfeng Liu1, Weidong Yang4, Chao Gao5, Jun Li1, Haifeng Zhang1, Yan Li5, Qin Cui3, Haichang Wang5, Ling Tao5, Jing Wang4, Michael J Quon6 & Feng Gao1,5

A close link between heart failure (HF) and systemic insulin resistance has been well documented, whereas myocardial insulin resistance and its association with HF are inadequately investigated. This study aims to determine the role of myocardial insulin resistance in ischemic HF and its underlying mechanisms. Male Sprague-Dawley rats subjected to myocardial infarction (MI) developed progressive left ventricular dilation with dysfunction and HF at 4 wk post-MI. Of note, myocardial insulin sensitivity was decreased as early as 1 wk after MI, which was accompanied by increased production of myocardial TNF-α. Overexpression of TNF-α in heart mimicked impaired insulin signaling and cardiac dysfunction leading to HF observed after MI. Treatment of rats with a specific TNF-α inhibitor improved myocardial insulin signaling post-MI. Insulin treatment given immediately following MI suppressed myocardial TNF-α production and improved cardiac insulin sensitivity and opposed cardiac dysfunction/remodeling. Moreover, tamoxifen-induced cardiomyocyte-specific insulin receptor knockout mice exhibited aggravated post-ischemic ventricular remodeling and dysfunction compared with controls. In conclusion, MI induces myocardial insulin resistance (without systemic insulin resistance) mediated partly by ischemia-induced myocardial TNF-α overproduction and promotes the development of HF. Our findings underscore the direct and essential role of myocardial insulin signaling in protection against post-ischemic HF.

Heart failure (HF) remains a leading cause of morbidity and mortality in the developed world. Laboratory and clinical studies document strong associations between insulin resistance and HF in both animal models and humans. In the Framingham Heart Study, diabetes is an independent risk factor for HF1. Diabetes, obesity, and associated insulin resistance triples risk of cardiovascular complications3,5. In non-diabetic patients with HF, insulin resistance is also a pathophysiological hallmark1,5. A 9-year prospective study of ~12,000 Swedish adults without prior HF demonstrates that systemic insulin resistance per se (without diabetes) predicts HF5. In the Cardiovascular Health Study, systemic insulin resistance is found to be associated with abnormal cardiac structure and risk of HF2. However, in these studies, only systemic insulin resistance is evaluated without considering myocardial insulin resistance. Given the importance of myocardial insulin signaling in protection against ischemia-induced injury and subsequent cardiac dysfunction/remodelling3, local myocardial insulin resistance per se and its association with post-ischemic HF are inadequately investigated. Therefore, rigorous investigation of ischemic HF in the context of impaired myocardial insulin signaling/action is warranted.

1Department of Aerospace Medicine, The Fourth Military Medical University, Xi’an 710032, China. 2Department of Physiology, The Fourth Military Medical University, Xi’an 710032, China. 3Department of Cardiac Surgery, Xijing Hospital, The Fourth Military Medical University, Xi’an 710032, China. 4Department of Nuclear Medicine, Xijing Hospital, The Fourth Military Medical University, Xi’an 710032, China. 5Department of Cardiology, Xijing Hospital, The Fourth Military Medical University, Xi’an 710032, China. 6Division of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, Baltimore, MD 21201, USA. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to M.J.Q. (email: quonm@medicine.umaryland.edu) or F.G. (email: fgao@fmmu.edu.cn)
Tumor necrosis factor-α (TNF-α) is a pro-inflammatory cytokine that promotes ischemic myocardial injury and cardiac dysfunction. After myocardial infarction (MI), TNF-α is locally released from ischemic cardiomyocytes and remains markedly elevated in advanced HF. TNF-α impairs insulin signaling and action, in part, by increasing serine phosphorylation of insulin receptor substrate-1 (IRS-1). This impairs insulin-stimulated tyrosine phosphorylation of IRS-1 that reduces binding of phosphatidylinositol 3-kinase (PI3K) to IRS-1. Consequently, activation of PI3K and downstream signaling molecules essential for regulation of glucose metabolism is impaired. In peripheral insulin targets including skeletal muscle and liver (in vitro and in vivo), TNF-α promotes insulin resistance by similar mechanisms. Thus, elevated local and/or circulating levels of TNF-α may contribute directly to myocardial insulin resistance.

Our previous studies have demonstrated that insulin exerts cardioprotective effects via PI3K/Akt-dependent survival signaling pathways that promote metabolic, anti-apoptotic and anti-inflammatory actions in various animals, including canine model of myocardial ischemia/reperfusion. Insulin-triggered survival signaling and actions in the heart are blunted in both systemic and myocardial insulin resistance. Systemic insulin resistance (that likely includes myocardial insulin resistance) increases infarct size in ischemic hearts leading to reduced functional recovery.

We therefore hypothesize that myocardial insulin resistance per se contributes to progression of post-ischemic HF. To test our hypothesis, we developed a rodent model of MI to study the effects of local cardiac TNF-α overexpression (adenoviral) and blockade (etanercept), insulin treatment, and cardiac insulin receptor signaling with respect to post-MI heart structure/function and subsequent HF.

**Results**

**Cardiac dysfunction and remodeling after MI.** We performed serial echocardiography in rats before MI, and 1, 2, 4, and 8 wk post-MI. Progressive LV dilation and heart dysfunction were observed over time (Fig. 1A–C). When compared with sham-operated rats, substantial reduction in EF (53 ± 3%) and increased LV diameter (LVEDD 0.45 ± 0.03 cm) were observed 1 wk post-MI. These abnormalities worsened over time with maximal LV dysfunction (EF 40 ± 3%) and dilation (LVEDD 0.62 ± 0.03 cm) achieved and maintained 4 to 8 wk post-MI.

**Myocardial insulin resistance occurred early in ischemic HF.** Basal and insulin-stimulated FDG uptake in rat hearts was assessed 30 min, 1 d, 1 wk, and 2 wk after MI (Fig. 1D). At baseline, FDG uptake in hearts of rats assigned to MI or sham groups was comparable. Insulin injection (10 U/kg) produced robust increases in cardiac FDG uptake in sham rats 30 min after surgery (Fig. 1E, left bars). By contrast, insulin-stimulated myocardial FDG uptake in hearts from MI rats was significantly lower than in sham rats 30 min after surgery (Fig. 1E, right bars). This suggests that myocardial insulin resistance is already evident early after MI.
uptake was even higher at the 30 min time point in rats post-MI (Fig. 1E). However, after 30 min, over time, progressive decrease in insulin-stimulated myocardial FDG uptake consistent with progressive increase in myocardial insulin resistance was observed in hearts of rats 1 d, 1 wk, and 2 wk post-MI (Fig. 1D,E).

Typically, myocardial insulin resistance follows, in parallel, changes in systemic whole body insulin resistance. In our model system with MI, we did not observe any significant differences in fasting plasma glucose (FPG), fasting plasma insulin (FIN), quantitative insulin sensitivity check index (QUICKI), oral glucose tolerance test (OGTT), or insulin tolerance test (ITT) when sham-operated and post-MI rats were evaluated and compared at 1 or 2 wk post-MI (Supplement Figure S1). Thus, MI caused local myocardial insulin resistance without systemic insulin resistance or glucose intolerance.

**Characterization of myocardial insulin resistance after surgically-induced MI.** Elevated basal Akt phosphorylation (without insulin stimulation) was induced by myocardial ischemia. This is well demonstrated both in our laboratory and others. Insulin stimulation of either sham or post-MI rats 1 d after operation caused robust increases in cardiac Akt phosphorylation. However, 1 wk post-MI, insulin-stimulated Akt phosphorylation was barely detectable (Fig. 2A). With respect to ERK 1/2 phosphorylation, both basal and insulin stimulated phosphorylation were a little higher in post-MI rats at 1 d when compared with sham animals. By 1 wk post-MI, basal ERK 1/2 phosphorylation was extremely elevated with no detectable insulin-stimulated increase (Fig. 2B). For p38 MAPK phosphorylation, there was no detectable insulin-stimulated increase in hearts of sham animals at baseline. Basal p38 MAPK phosphorylation was greatly increased in hearts 1 d post-MI, while insulin stimulation reduced phosphorylation. At 1 wk post-MI, basal phosphorylation levels were intermediate between those in hearts from sham rats and 1 d post-MI rats, while insulin now stimulated a robust increase in p38 MAPK phosphorylation (Fig. 2C). We next evaluated cell surface GLUT4 in heart as a downstream metabolic action (Fig. 2D). In sham animals, as expected, insulin stimulation caused increased GLUT4 translocation to the myocardial cell surface that predicts insulin-stimulated glucose uptake (Fig. 2D). In post-MI animals, insulin also stimulated GLUT4

**Figure 2.** Insulin signaling and cardiac plasma membrane GLUT4 in sham or MI rats. (A) Insulin stimulated phosphorylation of Akt was almost abolished 1 wk after MI. (B) Both basal and insulin stimulated phosphorylation of ERK1/2 was enhanced 1 wk after MI. In addition, 1 wk after MI, insulin did not further stimulate the elevated basal phosphorylation of ERK1/2. (C) Insulin treatment significantly increased phosphorylation of p38 MAPK 1 wk after MI. (D) Insulin-stimulated increase in cardiac plasma membrane GLUT4 was impaired 1 d after MI and abolished 1 wk after MI compared with sham. The bar graphs below the respective immunoblots represent quantification of multiple independent experiments from 3 animals (mean ± SEM). "Sham" means "non-MI + saline" at 30 min post-operation. *P < 0.05, **P < 0.01 vs. vehicle in sham, "P < 0.01 vs. vehicle in MI 1d, "P < 0.01 vs. insulin in sham."
translocation. However, the magnitude of this effect was smaller 1 d post-MI, and almost absent 1 wk post-MI. Thus, in hearts of rats subjected to MI, we observed local myocardial insulin resistance at the signaling level with respect to insulin-stimulated Akt phosphorylation, and at the functional level with respect to GLUT4 translocation (and presumably glucose uptake and metabolism).

Overexpression of TNF-α in heart mimics myocardial insulin resistance and HF caused by surgical MI. Chronic inflammation mediated by pro-inflammatory cytokines including TNF-α may contribute to systemic insulin resistance. However, effects of local cardiac overexpression of TNF-α on myocardial insulin resistance is unknown. Local overexpression of TNF-α in heart significantly increased cardiac TNF-α levels with the highest levels achieved 4 d after adenovirus infection (Fig. 3A). By 1 wk post-adenovirus infection, TNF-α levels in hearts infected with adTNF-α were declining back to levels seen 2 d post-adenovirus infection. Importantly, no detectable changes in circulating serum TNF-α were observed at 2 d and 4 d after adenovirus infection (lower limit of detection for the assay used = 25 pg/mL). This confirms that TNF-α overexpression was strictly limited to the heart reported above. Myocardial TNF-α was determined by immunohistochemistry staining in the left ventricular 7 d post-adenovirus infection. Compared with the adGFP-treated animals, TNF-α immunostaining was obviously present in adTNF-α-treated rats (Fig. 3B). Insulin injection (10 U/kg, i.p.) stimulates increased FDG uptake in hearts of control adGFP-treated rats (Fig. 3C,D). This was substantially blunted in adTNF-α-treated rats 1 wk post-adenovirus infection. When compared with adGFP-treated control animals, insulin-stimulated Akt phosphorylation (Fig. 3E) and translocation of GLUT4 (Fig. 3F) was impaired in adTNF-α-treated rats. P38 MAPK phosphorylation was increased in hearts infected with TNF-α with or without insulin stimulation. Thus, in hearts of rats subjected to MI, we observed local myocardial insulin resistance at the signaling level with respect to insulin-stimulated Akt phosphorylation, and at the functional level with respect to GLUT4 translocation (and presumably glucose uptake and metabolism).
when compared with adGFP-treated animals 1 wk post-MI (Fig. 3I,J). TNF-α levels were still significantly higher in adTNF-α-treated rats at 1 wk after MI when compared with adGFP-treated animals (Fig. 3K). Taken together, these results demonstrate that local cardiac overexpression of TNF-α mimics myocardial insulin resistance, and exacerbates poor heart function observed with surgically-induced MI.

TNF-α antagonism improved local myocardial insulin resistance caused by MI. We next treated our animal model with etanercept to block endogenous TNF-α signaling and action. Our preliminary experiments have shown that the presence of etanercept at this dose (300 μg/250 g body weight) had no significant effects on myocardial TNF-α production and cardiac function in non-MI (sham) rats. Pretreatment with etanercept during the first week after MI repressed local myocardial TNF-α production (circulating serum TNF-α levels were undetectable) (Fig. 4A). This substantially restored insulin-stimulated IRS-1 phosphorylation (Fig. 4D), Akt phosphorylation (Fig. 4E), and GLUT4 translocation (Fig. 4F) as well as myocardial FDG uptake (Fig. 4B,C) 1 wk post-MI. Moreover, etanercept treatment significantly suppressed p38 MAPK phosphorylation without or with insulin stimulation 1 wk post-MI (Fig. 4G). Thus, opposing TNF-α action preserved normal insulin signaling and action in myocardium post-MI. Etanercept treatment improved cardiac function and inhibited LV dilation at 1 wk after MI, while there were no significant differences in cardiac function or LV dilation when hearts from saline and etanercept-treated animals were evaluated 4 wk post-MI (Fig. 4H–J). Thus, our data suggest that TNF-α plays an important role in myocardial insulin resistance resulting from MI.

Early insulin treatment suppressed cardiac TNF-α production and improved myocardial insulin sensitivity and cardiac function post-MI. In a healthy context with intact PI3K signaling (e.g., normal insulin sensitivity with euglycemia), insulin treatment opposes pro-inflammatory signaling/actions while promoting anti-inflammatory signaling/actions in vasculature and macrophages to ameliorate cardiovascular pathophysiology. Early treatment given immediately after MI suppressed TNF-α production when...
compared with saline treatment (Fig. 5B). Our preliminary experiments have shown that insulin treatment had no significant effects on myocardial TNF-α production in non-MI (sham) rats. There were no significant changes in blood pressure and heart rate after the injection of insulin in MI rats. Early insulin treatment also improved subsequent insulin-stimulated myocardial FDG uptake and Akt phosphorylation 1 wk post-MI (Fig. 5A,C,D), and alleviated cardiac dysfunction and dilation 4 wk post-MI as evidenced by increased EF (Fig. 5E) and decreased LVESD (Fig. 5F). However, late insulin treatment initiated at 1 wk after MI when myocardial insulin resistance has developed exerted no beneficial effects on cardiac function and remodeling at 4 wk after MI.

**Aggravated post-ischemic LV dysfunction and remodeling in tamoxifen-induced cardiomyocyte-specific insulin receptor knockout (TCIRKO) mice.** To substantiate the role of myocardial insulin resistance in progression of HF, we determined specific effects of cardiac insulin signaling independent of systemic insulin resistance. Tamoxifen injections (50 mg/kg/d) for 3 d in MHC-MerCreMer/IR-/- mice induced Cre-mediated recombination to produce TCIRKO mice. Immunoblotting confirmed reduced concentration of insulin receptor protein by ~78% in cardiac muscle (P < 0.01) but not in skeletal muscle or liver (Fig. 6A). Insulin-stimulated myocardial Akt phosphorylation was almost entirely blocked in TCIRKO mice (Fig. 6B). No significant differences in heart weight/body weight were observed when control and TCIRKO mice were compared (Fig. 6C). Overnight-fasted (16 h) mice were injected i.p. with glucose (2 g/kg) for glucose tolerance tests (GTT) or insulin (0.75 U/kg) for insulin tolerance tests (ITT). No significant differences in GTT or ITT were observed among control and TCIRKO mice (Supplement Figure S2). Thus, systemic insulin sensitivity and glucose tolerance was not altered in TCIRKO mice. No significant differences in cardiac function or LV dimensions were observed when TCIRKO sham mice were compared with control mice (MHC-MerCreMer/IR+/+). By contrast with littermate controls, TCIRKO mice had exaggerated LV dysfunction and dilation 4 wk post-MI (EF 31.5 ± 2.4 vs. 45.3 ± 2.7%,
LVESV 31.5 ± 2.4 vs. 45.2 ± 2.7 μl, both P < 0.05) (Fig. 6E–H). Insulin treatment improved cardiac function and inhibited LV dilation only in littermate controls 4 wk post-MI (P < 0.05). These benefits were absent in TCIRKO mice (Fig. 6E–G). Thus, myocardial insulin resistance due to conditional knockout of heart insulin receptors alone was sufficient to greatly exacerbate post-ischemic HF.

Discussion

We have made three major findings in the present study. First, we observed that myocardial insulin resistance occurred as early as 1 wk following surgically-induced MI in rats, while systemic insulin sensitivity and glucose tolerance remained normal. Second, this myocardial insulin resistance was mediated partly by increased TNF-α production from the ischemic heart. Third, insulin treatment itself opposed myocardial insulin resistance caused by MI. This ameliorated post-ischemic cardiac dysfunction and subsequent HF. Moreover, cardiac specific insulin receptor knockout in adult mice exacerbated cardiac dysfunction and the development of HF post-MI. Indeed, the effects of cardiac-specific insulin receptor deletion occurred without causing changes in systemic insulin sensitivity. This determines an essential role of myocardial insulin signaling in protection against ischemic HF.

A close link between HF and systemic insulin resistance in humans has been recognized for decades. Most large clinical trials on HF report incident rates of diabetes of 15–35%24. Systemic insulin resistance often precedes development of HF suggesting that altered metabolic environment results in myocardial dysfunction and HF. In 1997, Botker et al. were the first to report myocardial insulin resistance in patients with metabolic syndrome25. Both systemic and cardiac insulin resistance are observed in non-diabetic patients or animals with moderate to advanced HF in most contexts26,27. Cardiac insulin resistance may occur as a result of systemic insulin resistance18,28. Amorim et al. have found that myocardial insulin resistance occurred at 2 wk after MI29, when the rats have developed heart failure (ejection fraction < 50%). In the present study, we found that myocardial insulin resistance occurred as early as 1 wk after MI (reduced insulin-stimulated GLUT4 translocation and FDG uptake) before the occurrence of heart failure (HF) without any detectable change in systemic insulin sensitivity, when ejection fraction was still higher than 50%. Thus, myocardial insulin resistance alone may be an early event in the development of ischemic HF independent of systemic insulin resistance and glucose intolerance in certain contexts.

One of the key characteristics of molecular signaling mechanisms underlying metabolic insulin resistance in the clinical setting is selective impairment in PI3K/Akt signaling pathways while other major branches of insulin signaling including Ras/MAPK (ERK1/2, p38MAPK and JNK) pathways remain intact or are even enhanced30–33. In the presence of myocardial insulin resistance 1 wk after MI, we observed blunted insulin stimulation of Akt and ERK1/2 phosphorylation with concomitant enhanced p38 MAPK phosphorylation characteristic of pathway-selective insulin resistance. Local TNF-α overexpression caused cardiac insulin resistance while exacerbating functional and structural sequelae of post-MI. As TNF-α can induced self expression in some pathological conditions34,35, etanercept treatment may block TNF-α-induced self expression after MI and then repressed local myocardial TNF-α
production. Moreover, etanercept treatment partially restored myocardial insulin sensitivity and improved cardiac function at 1 wk after MI, but did not improve cardiac function and remodeling at 4 wk after MI. The reason for this may be that beneficial cardiac effects with etanercept early after MI is offset by its adverse cardiovascular effects such as potentiating platelet–monocyte aggregation and causing TNF-α imbalance in the long-term development of ischemic heart failure36,37. It should be noted that the mechanisms of myocardial insulin resistance post-MI are multi-factorial and complex. TNF-α overproduction is only one of the important mechanisms and further study still needs to be done to reveal the complex mechanisms.

Our study showed that insulin treatment activated Akt and ERK1/2, while reducing phosphorylation of p38 MAPK 1 d after MI. Thus, insulin therapy at the appropriate time can reverse pathophysiology underlying pathway-selective insulin resistance in heart that contributes to ischemic damage, myocardial dysfunction and HF. It seems likely that early insulin therapy improves insulin signaling and action, in part, through rebalancing insulin signaling between PI3K/Akt and MAPK insulin signaling branches to mediate anti-inflammatory actions opposing detrimental TNF-α actions in heart. Insulin treatment also exerts anti-apoptotic and anti-oxidative/nitrative stress effects that complement insulin anti-inflammatory actions36. This is supported by recent IMMEDIATE trial that immediate GIK administration was associated with lower rates of the composite outcome of cardiac arrest or in-hospital mortality in patients with ST segment elevation. Our study further showed that late insulin administration (1 wk after MI) failed to exert beneficial effects, which may be due to blunted insulin-stimulated Akt phosphorylation.

To further confirm the role of myocardial insulin resistance in the development of ischemic HF, we used TCIRKO mice to achieve temporal control of insulin receptor disruption in the heart. This is an important advantage over the previous CIRKO model where absence of cardiac insulin receptors during development has resulted in cardiac pathology as shown by decreased myocyte size and modestly reduced cardiac function even at baseline40. In this study, no significant differences in heart weight/body weight ratio and cardiac function were observed when control and TCIRKO mice were compared at baseline. Importantly, loss of cardiac insulin receptors led to aggravated LV dysfunction and LV dilation after MI (without altering systemic insulin sensitivity), suggesting that myocardial insulin resistance contributes to the progression of ischemic HF. Taken together, our data showed that myocardial insulin resistance is not only a result of MI but also a contributing factor of cardiac dysfunction after MI.

In the clinical setting, anti-diabetic agents aim to improve systemic insulin sensitivity, while some of them exert no beneficial effects on HF patients40. Our findings reveal that myocardial insulin resistance occurs early in the development of HF, which is independent of systemic insulin resistance, and contributes to the development of HF. Therefore, the intervention specifically targeted against myocardial insulin resistance may represent a potential therapeutic strategy for HF.

In summary, myocardial insulin resistance, independent of systemic insulin resistance, is an early event in the development of ischemic HF following MI. Impaired myocardial insulin action is at least partly mediated by over-production of TNF-α. This may be that beneficial cardiac effects with etanercept early after MI is offset by its adverse cardiovascular effects such as potentiating platelet–monocyte aggregation and causing TNF-α imbalance in the long-term development of ischemic heart failure36,37. It should be noted that the mechanisms of myocardial insulin resistance are multi-factorial and complex. TNF-α overproduction is only one of the important mechanisms and further study still needs to be done to reveal the complex mechanisms.

Materials and Methods

Myocardial infarction protocol. All animal experiments were performed in accordance with the National Institutes of Health Guidelines on the Use of Laboratory Animals and were approved by The Fourth Military Medical University Committee on Animal Research. Male Sprague-Dawley rats (200–230 g) were anesthetized with 3% pentobarbital sodium. As described41, myocardial infarction was initiated after exposing the heart through a left thoracotomy at the fourth rib by using 4–0 silk to ligate the left anterior descending coronary artery (LAD) permanently near its origin from the left coronary artery. In sham rats, the silk suture was passed underneath the left anterior descending artery without ligation. Then the sham rats received saline administration.

Echocardiography measurements. Serial doppler echocardiography was performed with the ACUSON Sequoia 512 ultrasound machine (Siemens) before the operation and 1, 2, 4 and 8 wk after the operation. A 14-MHz probe was used to obtain two-dimensional, and M-mode imaging from parasternal short-axis view at the level of the papillary muscles and the apical four-chamber view. LV end-systolic and end-diastolic diameters (LVESD and LVEDD respectively) were measured. LV fractional shortening (FS) was calculated as (LVEDD–LVEDD)/LVEDD × 100%. Left ventricular end-diastolic volume (EDV) and end systolic volume (ESV) were calculated according to the formula by Teichholz et al.42. Ejection fraction (EF) was calculated as (EDV–ESV)/EDV × 100%.

Assessment of systemic insulin sensitivity. Fasting plasma glucose (FPG) was analyzed by using standard glucose oxidase methods in rats fasted for 12h. Fasting plasma insulin (FIN) was measured by using an enzyme linked immunosorbent assay. Quantitative insulin sensitivity check index (QUICKI) was calculated for estimating systemic insulin sensitivity. QUICKI = 1/[(log(FIN) + log(FPG)].43 Rats were also given an oral glucose (2 g/kg) challenge or an i.p. injection of insulin (0.5 U/kg) (Novo Nordisk, China) to assess whole body glucose tolerance and insulin sensitivity. Whole blood glucose levels were determined at 0, 30, 60, 90 and 120 min after glucose challenge for oral glucose tolerance test (OGTT), or at 0, 30, 60, 90, 120, and 240 min for insulin tolerance test (ITT) (tail clipping used to obtain blood samples).

Assessment of insulin-stimulated myocardial FDG uptake. Insulin-stimulated myocardial [18F]-fluorodeoxyglucose (FDG) uptake was measured as reported44. Briefly, animals were intravenously injected with ~1 mCi of FDG (tail vein) and subsequent PET/CT images were acquired (microPET/CT scanner; Medison, Budapest, Hungary). Insulin stimulation was initiated in overnight fasted rats through i.p. injection of 10 U/kg insulin 30 min before beginning image acquisition. Insulin-stimulated myocardial FDG uptake was assessed using
the standardized uptake value SUV = C/(D/M) where C is activity concentration in regions of interest (ROI), D is the injected dose, and M is the body weight. ROI of identical size were chosen on myocardium outside of the infarcted region. Data reported are the maximal value of SUV (SUVmax) during the last 30 min of scanning.

**Whole tissue extract and plasma membrane fractionation.** Insulin stimulation was induced in fasted rats through i.p. injection of 10 U/kg insulin. After 30 min of insulin or saline injection, animals were euthanized and non-infarcted LV myocardial tissues were harvested. Whole tissue extract was prepared by homogenizing myocardium tissue in ice-cold lysis buffer. The lysates were centrifuged and the supernatants were retained. Heart plasma membrane (PM) fraction was performed as described previously46. Ventricle tissue was homogenized in buffer A containing (in mmol/L, pH 7.0): 10 NaHCO₃, 5 NaN₃, and then centrifuged at 7000 × g for 20 min. The pellet was resuspended in buffer B (10 mmol/L Tris-Cl, pH 7.4), and centrifuged at 200 × g for 20 min. The supernatant was gently layered on top of a 20% (vol/vol) percoll gradient in buffer C (in mmol/L: 25 sucrose, 10 Tris-Cl (pH 7.4), 2 EDTA) and centrifuged at 55,000 × g for 1 h. The band with density of 1.030 was aspirated and pelleted by centrifugation at 170,000 × g for 1 h and resuspended in buffer C as PM solution. Protein concentration of whole tissue or PM solution was determined using a BCA protein assay. Glucose transporter 4 (GLUT4) content in PM was determined by immunoblotting using standard methods.

**Immunoblotting.** Whole tissue proteins or PM proteins were separated on a SDS-PAGE Electrophoresis System as described previously46. Primary antibodies used were: phospho-IRS-1 (Tyr1222), IRS-1, phospho-Akt (Ser 473), Akt, phospho-ERK1/2 (Thr202/Tyr204), ERK1/2, phospho-JNK (Thr183/Tyr185), JNK, GLUT-4 and G3 from Cell Signaling Technology; phospho-p38 MAPK (Thr202/Tyr204) and p38 MAPK from Abcam.

**Overexpression of TNF-α by adenovirus infection.** Serotype 5 adenoviral vectors encoding TNF-α were provided by GeneChem, Shanghai, China. In brief, the cDNA for TNF-α was cloned into pMD19-T simple vector and then transferred into pAdTrack-CMV, resulting in pAdTrack-TNF-α. The shuttle vectors were used to generate recombinant adenoviral vectors encoding TNF-α (Ad-TNF-α). Adenoviral vectors encoding green fluorescent protein (Ad-GFP) were used as control. Adenoviruses were purified by double cesium chloride gradient ultracentrifugation. Viral titer was determined by plaque assay and expressed as plaque-forming units (pfu).

Adenovirus-mediated gene transfer to cardiac myocytes was performed as previously described52. A 24-gauge catheter containing 0.1 ml of viral solution (7.5 × 10⁶ pfu) was advanced from the apex of the left ventricle to the aortic root. The aorta and pulmonary arteries were then clamped distal to the site of the catheter and the solution injected. The clamp was maintained for 45 sec while the heart is pumping against a closed system isovolumically. This allows the solution that contains the adenovirus to circulate down the coronary arteries and perfuse the heart without direct manipulation of the coronaries. After that, the clamp on the aorta and pulmonary artery was released. Insulin-stimulated myocardial FDG uptake and Akt phosphorylation and GLUT4 membrane translocation were measured as previously described in non-MI rats 1 wk after adenovirus infection.

**Determination of myocardial and serum TNF-α levels.** Myocardial and serum TNF-α levels were measured as described previously48. Heart tissue samples for determination of myocardial TNF-α were obtained from the non-infarcted area of LV. The protein content of the samples was measured with the use of a protein assay kit (bovine serum albumin was used as a standard control). Quantitative expression of the TNF-α was assessed using a rat ELISA kit (Neobioscience Technology Co., Ltd). The sensitivity range of this assay is 25 pg/mL–20000 pg/mL.

**Antagonism of TNF-α action with etanercept.** Rats that had surgically induced MI (or control rats) were treated with the TNF-α inhibitor etanercept (Immunex, Seattle, Wash) by i.p. injection (300 μg/250 g body weight) 2 d prior to coronary artery ligation and every 2 d thereafter in the first week after MI. The dose and timing of etanercept administration was based on early studies49,50 and validated in our preliminary experiments. Insulin-stimulated myocardial FDG uptake and Akt phosphorylation and GLUT4 membrane translocation were measured as previously described for etanercept-treated rats at 1 wk after MI.

**Systemic insulin treatment.** Subcutaneous daily injection with insulin (0.5 U/ml, 1ml/kg/d) was administered in the first week after MI to investigate the effect of insulin on myocardial insulin sensitivity and the development of ischemic HF. Insulin-stimulated myocardial FDG uptake was measured as previously described in insulin-treated rats 1 wk after MI. Echocardiographic and hemodynamic analysis was performed in insulin-treated animals at 4 wk after MI.

**Inducible cardiomyocyte-specific insulin receptor knockout mice.** We obtained mice from the Model Animal Research Centre of Nanjing University that were homozygous for loxP-flanked insulin receptor exon, and positive for tamoxifen–inducible Cre recombinase driven by the cardiomyocyte-specific α-myosin heavy chain (MHC) promoter (MHC-MerCreMer/IR⁺/⁺). Male mice aged 8–10 wk were injected intraperitoneally with tamoxifen (50 mg/kg) for 3 d to induce insulin receptor gene excision in cardiomyocytes. Age-matched male littermates (MHC-MerCreMer/IR⁻/⁻) were used as control animals. Littermate control mice were also treated with tamoxifen in an identical manner. After that, HW/BW ratio was measured and echocardiography was done before MI in knockout mice and controls.

**Myocardial infarction protocol in mice.** Both knockout mice and controls were subjected to LAD ligation after the tamoxifen treatment. The mice were anesthetized with pentobarbital sodium (50 mg/kg i.p.) and connected to a rodent ventilator (volume-cycled ventilator supplying supplemental oxygen with a tidal volume of 2.5 ml and a respiratory rate of 120 beats/min) using a 20 G i.v. catheter. Via thoracotomy, the pericardial sac was opened and a 7–0 silk suture was passed beneath the root of LAD and tied to induce ischemia of the left ventricle. Finally the
References

1. Kannel, W. B., Hjortland, M. & Castelli, W. P. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34, 29–34 (1974).

2. Kannel, W. B. & McGee, D. L. Diabetes and cardiovascular disease. The Framingham study. JAMA 241, 2035–2038 (1979).

3. Fox, C. S. et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 115, 1344–1350 (2007).

4. Swan, J. W. et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol 30, 527–532 (1997).

5. ALZadali, M. A. et al. Insulin resistance is highly prevalent and is associated with reduced exercise tolerance in nondiabetic patients with heart failure. J Am Coll Cardiol 53, 747–753 (2009).

6. Inglessis, E., Sundstrom, J., Arnlov, J., Zethelius, B. & Lind, L. Insulin resistance and risk of congestive heart failure. JAMA 294, 334–341 (2005).

7. Banerjee, D. et al. Reduced glucose metabolism in primary cultured myocardial cells from patients with chronic heart failure. J Am Coll Cardiol 62, 1771–1783 (2013).

8. Xing, W. et al. Insulin resistance and risk of incident heart failure: Cardiovascular Health Study. Circ Heart Fail 6, 364–370 (2013).

9. Xing, W. et al. Insulin resistance and risk of incident heart failure: Cardiovascular Health Study. Circ Heart Fail 6, 364–370 (2013).

10. Kim, J. A. et al. Metabolic remodelling in human heart failure. J Thorac Cardiovasc Surg 143, 143–150 (2012).

11. Kim, J. A. et al. Systematic review of the metabolic effects of antihypertensive treatment in patients with chronic heart failure. J Thorac Cardiovasc Surg 143, 143–150 (2012).

12. de Alvaro, C., Tero, T., Hernandez, R. & Lorenzo, M. Tumor necrosis factor-alpha induces myocardial inflammation and apoptosis in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner. J Biol Chem 279, 17070–17078 (2004).

13. Cheung, A. T., Wang, J., Ree, D., Kolls, J. K. & Bryer-Ash, M. Tumor necrosis factor-alpha induces hepatic insulin resistance in obese Zucker (fa/fa) rats via interaction of leukocyte antigen-related tyrosine phosphatase with focal adhesion kinase. Diabetes 49, 810–819 (2000).

14. Gao, F. et al. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation 105, 1497–1502 (2002).

15. Yu, Q. et al. Effective glycaemic control critically determines insulin cardioprotection against ischaemia/reperfusion injury in anaesthetized dogs. Cardiovasc Res 100, 238–247 (2014).

16. Yu, Q., Gao, F. & Ma, X. L. Insulin says NO to cardiovascular disease. Cardiovasc Res 89, 516–524 (2011).

17. Bertrand, L., Horman, S., Beaulève, C. & Vanoverschelde, J. L. Insulin signalling in the heart. Cardiovasc Res 79, 238–248 (2008).

18. Mazumder, P. K. et al. Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes 53, 2366–2374 (2004).

19. Klavetter, J. et al. Association of DJ-1/PTEN/AKT- and ASK1/p38-mediated cell signalling with ischaemic cardiomyopathy. Cardiovasc Res 97, 66–76 (2013).

20. Ji, L. et al. Insulin attenuates myocardial ischemia/reperfusion injury via reducing oxidative/nitritive stress. Am J Physiol Endocrinol Metab 298, E871–E880 (2010).

21. Olefsky, J. M. & Glass, C. K. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 72, 219–246 (2010).

22. Jeschke, M. G., Klein, D., Bolder, U. & Einspanier, R. Insulin attenuates the systemic inflammatory response in endotoxemic rats. J Biol Chem 289, 20377–20385 (2014).

23. Li, J. et al. Insulin inhibits tumor necrosis factor-alpha induction in myocardial ischemia/reperfusion: role of Akt and endothelial nitric oxide synthase phosphorylation. Crit Care Med 36, 1551–1558 (2008).

24. Cohen-Solal, A., Beauvais, F. & Logeart, D. Heart failure and diabetes mellitus: epidemiology and management of an alarming association. J Card Fail 14, 615–625 (2008).

25. Verloes, R., Moller, S., Schmitz, O., Bagger, J. P. & Nielsen, T. T. Myocardial insulin resistance in patients with diabetes mellitus. J Clin Invest 100, 1919–1927 (1997).

26. Nikolaidis, L. A. et al. The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy. Cardiovasc Res 61, 297–306 (2004).

27. Tuunanen, H. & Knutti, J. Metabolic remodelling in human heart failure. Cardiovasc Res 90, 251–257 (2011).

28. Iikuni, O. et al. Antioxidant treatment normalizes mitochondrial energetics and myocardial insulin sensitivity independently of changes in systemic metabolic homeostasis in a mouse model of the metabolic syndrome. Mol Med Cardiol 85, 104–116 (2015).

29. Amorim, P. A. et al. Myocardial infarction in rats causes partial impairment in insulin response associated with reduced fatty acid oxidation and mitochondrial gene expression. J Thorac Cardiovasc Surg 140, 1160–1167 (2010).

30. Formoso, G. et al. Dehydroepiandrosterone mimics acute actions of insulin to stimulate production of both nitric oxide and endothelin 1 via distinct phosphatidylinositol-3-kinase- and mitogen-activated protein kinase-dependent pathways in vascular endothelium. Mol Endocrinol 20, 1133–1143 (2006).

31. Potenza, M. A., Maraschio, F. L., Tarquinio, M., Quon, M. J. & Montagnani, M. Treatment of spontaneously hypertensive rats with rosiglitazone and/or enalapril restores balance between vasodilator and vasoconstrictor actions of insulin with simultaneous improvement in hypertension and insulin resistance. Diabetes 55, 3594–3603 (2006).

32. Kim, J. A., Montagnani, M., Koh, K. K. & Quon, M. J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 113, 1888–1904 (2006).

33. Lightell, D. J., Moss, S. C. & Woods, T. C. Loss of canonical insulin signaling accelerates vascular smooth muscle cell proliferation and migration through changes in p27kip1 regulation. Endocrinology 152, 651–658 (2011).

34. Subramaniyan, D. et al. TNF-alpha-induced self expression in human lung endothelial cells is inhibited by native and oxidized alpha1-antitrypsin. Int J Biochem Cell Biol 40, 258–271 (2008).

35. Lockhart, A. D. et al. alpha1-Antitrypsin modulates lung endothelial cell inflammatory responses to TNF-alpha. Am J Respir Cell Mol Biol 49, 143–150 (2013).

36. Padfield, G. J. et al. Cardiovascular effects of tumour necrosis factor alpha antagonist in patients with acute myocardial infarction: a first in human study. Heart 99, 1330–1335 (2013).
37. Gao, C. et al. TNF-alpha antagonism ameliorates myocardial ischemia-reperfusion injury in mice by upregulating adiponectin. *Am J Physiol Heart Circ Physiol* **308**, H1583–H1591 (2015).

38. Selker, H. P. et al. Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial. *JAMA* **307**, 1925–1933 (2012).

39. Belke, D. D. et al. Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. *J Clin Invest* **109**, 629–639 (2002).

40. Khalaf, K. I. & Taegtmeyer, H. After avandia: the use of antidiabetic drugs in patients with heart failure. *Tex Heart Inst J* **39**, 174–178 (2012).

41. Gan, X. T. et al. Probiotic administration attenuates myocardial hypertrophy and heart failure after myocardial infarction in the rat. *Circ Heart Fail* **7**, 491–499 (2014).

42. Teichholz, L. E., Koeullen, T., Herman, M. V. & Gorlin, R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. *Am J Cardiol* **37**, 7–11 (1976).

43. Chen, H., Sullivan, G. & Quon, M. J. Assessing the predictive accuracy of QUICKI as a surrogate index for insulin sensitivity using a calibration model. *Diabetes* **54**, 1914–1925 (2005).

44. Ciccarelli, M. et al. G protein-coupled receptor kinase 2 activity impairs cardiac glucose uptake and promotes insulin resistance after myocardial ischemia. *Circulation* **123**, 1953–1962 (2011).

45. Zhang, Q. J. et al. Swim training sensitizes myocardial response to insulin: role of Akt-dependent eNOS activation. *Cardiovasc Res* **75**, 369–380 (2007).

46. Zhang, H. F. et al. Role of insulin in the anti-apoptotic effect of glucose-insulin-potassium in rabbits with acute myocardial ischemia and reperfusion. *Apoptosis* **9**, 777–783 (2004).

47. Del, M. F. & Hajjar, R. J. Efficient viral gene transfer to rodent hearts in vivo. *Methods Mol Biol* **219**, 179–193 (2003).

48. Francis, J., Chu, Y., Johnson, A. K., Weiss, R. M. & Felder, R. B. Acute myocardial infarction induces hypothalamic cytokine synthesis. *Am J Physiol Heart Circ Physiol* **286**, H2264–H2271 (2004).

49. Krasinski, K., Spyridopoulos, I., Kearney, M. & Losordo, D. W. In vivo blockade of tumor necrosis factor-alpha accelerates functional endothelial recovery after balloon angioplasty. *Circulation* **104**, 1754–1756 (2001).

50. Gurantz, D. et al. Etanercept or intravenous immunoglobulin attenuates expression of genes involved in post-myocardial infarction remodeling. *Cardiovasc Res* **67**, 106–115 (2005).

**Acknowledgements**

This work was supported by grants from the National Basic Research Program of China (No. 2013CB531204 to F.G.), the State Key Program of National Natural Science Foundation of China (No. 81030005 to F.G.) and the National Natural Science Foundation of China (Nos. 81200174 to F.F., 31371150 to J.L.) and the National High Technology Research and Development Program (2014AA020542 to J.L.).

**Author Contributions**

The contributions of the authors to the submitted work are as follows: F.G. defined the research theme and revised the manuscript critically. F.F. and K.Z. designed the methods, researched data and wrote the paper. J.X., W.Y. and J.W. carried out microPET/CT scan. Echocardiography measurements were performed by C.G., C.L. and J.L. Y.Z. prepared and provided tamoxifen-induced cardiomyocyte-specific insulin receptor knockout mice. Y.L., Q.C. and H.W. analyzed the data and interpreted the results. J.L., H.Z., L.T. and M.Q. reviewed and edited the manuscript.

**Additional Information**

Supplementary information accompanies this paper at http://www.nature.com/srep

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Fu, F. et al. Direct Evidence that Myocardial Insulin Resistance following Myocardial Ischemia Contributes to Post-Ischemic Heart Failure. *Sci. Rep.* **5**, 17927; doi: 10.1038/srep17927 (2015).